Research
The label a bulk drug substance is supposed to carry
Drug labeling law lets a container skip directions for use in a few defined situations. Two of them cover bulk material and laboratory work, and each prescribes its own wording and its own conditions.
Why a container would carry no directions at all
A drug is normally misbranded unless its labeling bears adequate directions for use. Two articles on this site cover that requirement and the main exemption from it.
There is a whole subpart of exemptions, though, and two of them describe material that was never meant to reach a patient in that form.
One covers a drug in a bulk package headed for further manufacturing. The other covers a drug supplied for teaching, law enforcement, research or analysis.
Each grants relief from the same statutory requirement. Each also attaches conditions, and the conditions are the informative part.
What the bulk exemption covers
The first exemption is written around a package type and a destination.
It applies to "A drug in a bulk package, except tablets, capsules, or other dosage unit forms, intended for processing, repacking, or use in the manufacture of another drug."
Finished dosage units are expressly outside it. A bottle of tablets is not bulk material for these purposes, whatever it is called.
The exemption is not automatic on that description alone. It is conditioned on what the label says.
The wording the regulation actually prescribes
This is the sentence most worth carrying away, because the prescribed phrase is specific.
The exemption applies "if its label bears the statement" that follows, and the statement is "Caution: For manufacturing, processing, or repacking."
A second statement is layered on top where relevant. If substantially all the dosage forms it could be dispensed in would be prescription products, the label also carries "Rx only."
There is a veterinary variant with its own prescribed sentence. In each case the regulation supplies the words rather than describing an idea.
The exemption switches off for a new drug
The carve-out is where this section gets interesting, and it is easy to miss at the end of a long sentence.
The text: "the exemption shall not apply to a substance intended for a use in manufacture, processing, or repacking which causes the finished article to be a new drug."
Three routes then put it back on. An approved application can cover the production and delivery of the substance by named persons. A pending application can hold it open, provided the bulk drug is not exported and the finished product is not further distributed until approval.
The third route is a longer label. Where no application is approved, the caution statement is supplemented by the words "in the preparation of a new drug or new animal drug limited by Federal law to investigational use."
The teaching and research exemption
The second exemption is a single sentence, and every clause in it does work.
It applies to a drug "shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry, or medicine not involving clinical use."
The list continues: "or engaged in law enforcement, or in research not involving clinical use, or in chemical analysis, or physical testing."
And it closes with a use restriction: the drug "is to be used only for such instruction, law enforcement, research, analysis, or testing."
Three conditions inside one sentence
Read slowly, that sentence sets three separate tests rather than one.
The first is about the person. They must be regularly and lawfully engaged in one of the named activities, so an occasional or self-described involvement is not what the words describe.
The second is about the activity. Instruction and research both carry the qualifier "not involving clinical use," which excludes use in the care of a person.
The third is about what happens next. The material is to be used only for those purposes, so the exemption travels with the use and not merely with the shipment.
What the regulation does not say
Part 201 was read in full for this, and one finding is an absence worth stating precisely.
The phrase research use only appears in none of the 75 sections of part 201. The nearest text is the heading of a separate section about radioactive drugs given to human research subjects under a different rule, which prescribes no label phrase of that kind.
That is a statement about part 201 and nothing wider. Other parts of the drug regulations were not searched for the phrase, and no conclusion should be drawn about them.
A separate mechanism exists for shipping an investigational drug for laboratory research, under the investigational new drug rules. That route is covered in its own article here and is not the same as either exemption above.
What this is good for
These sections describe the paperwork of an industrial supply chain, and they are useful mainly as a reference point.
The first thing they give is prescribed wording. Where a bulk drug substance is moving toward further manufacture, the regulation names the sentence its label is to bear.
The second is a set of conditions attached to a person and a purpose rather than to a product. In the teaching and research exemption, who is receiving it and what it will be used for are part of the test.
This article takes no position on how any particular vial or transaction relates to either section. The category of material sold as a laboratory chemical is discussed separately on this site, and that article reaches no legal conclusion either.
Key takeaways
- Drug labeling law contains a subpart of exemptions from the requirement to bear adequate directions for use.
- One covers bulk packages headed for processing, repacking or manufacture into another drug, excluding dosage unit forms.
- That exemption is conditioned on a prescribed caution statement, plus the prescription-only statement where relevant.
- It switches off where the finished article would be a new drug, unless an approved or pending application applies.
- A second exemption covers drugs for instruction, law enforcement, research not involving clinical use, chemical analysis or physical testing.
- That one attaches conditions to the person, the activity and the eventual use, not only to the shipment.
- The phrase research use only appears nowhere in the 75 sections of that part of the labeling regulations.
- A separate route exists for shipping an investigational drug for laboratory research, under different rules.
Frequently asked questions
What does the bulk drug labeling exemption require?
It applies to a drug in a bulk package, other than tablets, capsules or other dosage unit forms, intended for processing, repacking or use in the manufacture of another drug. The relief from adequate directions for use is conditioned on the label bearing a prescribed caution statement for manufacturing, processing or repacking. Where substantially all the dosage forms it might be dispensed in would be prescription products, the label also carries the prescription-only statement.
Does that exemption always apply to bulk material?
No. It does not apply to a substance whose use in manufacture, processing or repacking causes the finished article to be a new drug, unless one of three conditions is met. An approved application may cover the production and delivery of the substance by named persons. A pending application may hold it open, provided the bulk drug is not exported and the finished product is not further distributed until approval. Otherwise the caution statement has to be supplemented with words limiting it to the preparation of a new drug restricted to investigational use.
What is the teaching and research exemption?
It relieves a drug from the adequate directions for use requirement in a defined situation. The drug must be shipped or sold to, or in the possession of, persons regularly and lawfully engaged in one of the named activities. Those are instruction in pharmacy, chemistry or medicine not involving clinical use, law enforcement, research not involving clinical use, chemical analysis, and physical testing. The drug is to be used only for those purposes.
Does the phrase research use only come from a regulation?
Not from this one. Searched in full, the phrase appears in none of the 75 sections of the part of the drug labeling regulations that contains these exemptions. The closest text is the heading of a section about radioactive drugs administered to human research subjects under a separate rule, and that section prescribes no label phrase of that kind. That finding is scoped to this part alone; other parts of the drug regulations were not searched.
How is this different from shipping an investigational drug to a laboratory?
That is a different mechanism under a different part of the regulations, covered in its own article here. The two exemptions described above sit in the labeling rules and are about relief from adequate directions for use. The investigational route sits in the clinical trial rules and is about when an application is needed before a drug may be shipped for laboratory research.
Does this settle anything about buying research-labeled material?
No, and it is not written to. These are two labeling exemptions with conditions attached to a package type, a person and a purpose. Nothing above states whether any particular purchase, shipment or possession falls inside or outside either one. The separate article on research-labeled vials describes what that category is and likewise reaches no legal conclusion.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Title 21 Code of Federal Regulations section 201.122, Drugs for processing, repacking, or manufacturing — the exemption from section 502(f)(1) of the act for a drug in a bulk package other than dosage unit forms, the prescribed caution statement for manufacturing, processing or repacking, the additional prescription-only and veterinary statements, the carve-out where the finished article would be a new drug, and the three conditions at (a), (b) and (c) including the supplemental investigational-use wording — Electronic Code of Federal Regulations, Office of the Federal Register, December 2007
- Title 21 Code of Federal Regulations section 201.125, Drugs for use in teaching, law enforcement, research, and analysis — the exemption from section 502(f)(1) of the act for a drug shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry or medicine not involving clinical use, in law enforcement, in research not involving clinical use, or in chemical analysis or physical testing, and the requirement that it be used only for those purposes — Electronic Code of Federal Regulations, Office of the Federal Register, February 1976
- Title 21 Code of Federal Regulations section 201.129, Drugs; exemption for radioactive drugs for research use — the exemption from section 502(f)(1) of the act for a radioactive drug given to human research subjects to obtain basic research information on metabolism or human physiology, under the conditions in section 361.1 of the chapter, cited here as the only section of part 201 whose text touches the words research use — Electronic Code of Federal Regulations, Office of the Federal Register, February 1976